Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Impedimed Limited ( (AU:IPD) ) is now available.
ImpediMed Limited held its Annual General Meeting where all proposed resolutions were passed, including the remuneration report and the re-election of board members Ms. Christine Emmanuel-Donnelly and Mr. McGregor Grant. The successful passage of these resolutions indicates strong shareholder support and stability in the company’s governance, which could positively impact its strategic direction and stakeholder confidence.
The most recent analyst rating on (AU:IPD) stock is a Buy with a A$0.13 price target. To see the full list of analyst forecasts on Impedimed Limited stock, see the AU:IPD Stock Forecast page.
More about Impedimed Limited
ImpediMed Limited operates in the medical technology industry, specializing in non-invasive medical devices that measure, monitor, and manage fluid status and body composition. The company focuses on providing solutions for healthcare professionals to improve patient care and outcomes.
Average Trading Volume: 1,744,826
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$79.46M
Learn more about IPD stock on TipRanks’ Stock Analysis page.